Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
SPRY
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
globenewswire.com
8 hours ago
zacks.com
9 hours ago
seekingalpha.com
11 hours ago
Earnings Growth
YoY
Current
Estimates
Q3.23
N/A
-0.16
vs -0.50
Q4.23
N/A
-0.07
vs 0.77
Q1.24
N/A
-0.11
vs -0.16
Q2.24
N/A
-0.13
vs -0.18
Q3.24
N/A
-0.20
vs -0.16
Q4.24
+843%
0.52
vs -0.07
Q1.25
N/A
-0.35
vs -0.11
Q2.25
N/A
-0.46
vs -0.13
Q3.25
N/A
-0.44
vs -0.20
Q4.25
N/A
-0.30
vs 0.52
Sales Growth
YoY
Current
Estimates
Q3.23
-100%
NA vs 189K
Q4.23
+100%
NA vs -1316000
Q1.24
-100%
NA vs 20K
Q2.24
+4900%
500K vs 10K
Q3.24
NA
2.1M vs NA
Q4.24
NA
86.6M vs NA
Q1.25
NA
8M vs NA
Q2.25
+3043%
15.7M vs 500K
Q3.25
+1249%
27.9M vs 2.1M
Q4.25
-66%
29.1M vs 86.6M
Return on Equity
QoQ
Q1.23
-4%
-0.04
vs -0.05
Q2.23
-7%
-0.07
vs -0.04
Q3.23
-6%
-0.06
vs -0.07
Q4.23
-3%
-0.03
vs -0.06
Q1.24
-5%
-0.05
vs -0.03
Q2.24
-6%
-0.06
vs -0.05
Q3.24
-10%
-0.10
vs -0.06
Q4.24
+19%
0.19
vs -0.10
Q1.25
-15%
-0.15
vs 0.19
Q2.25
-23%
-0.23
vs -0.15
Institutionnal Ownership
QoQ
Q1.23
95
95
vs 74
28%
Q2.23
99
99
vs 95
4%
Q3.23
107
107
vs 99
8%
Q4.23
105
105
vs 107
-2%
Q1.24
118
118
vs 105
12%
Q2.24
121
121
vs 118
3%
Q3.24
162
162
vs 121
34%
Q4.24
175
175
vs 162
8%
Q1.25
189
189
vs 175
8%
Q2.25
192
192
vs 189
2%
Quote Panel
Key Metrics
Forecast
1179%2026-Revenue
-68%2026-EPS
-176%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Hold
Price Target
0.00(N/A)
Number of analyst
0
Last analyst upgrade/downgrade
Scotiabank
initialisePrevious: Not converted
2025-03-07
Now: Outperform
Cantor Fitzgerald
initialisePrevious: Not converted
2024-08-19
Now: Overweight
Raymond James
upgradePrevious: Outperform
2024-08-12
Now: Strong Buy
Raymond James
initialisePrevious: Not converted
2024-07-25
Now: Outperform
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
NASDAQ
Unprofitable
Unprofitable
-0.50Â ( -3.44%)
After-hours 14.49$0.46 (3.28%)
Relative Strenght
75
Volume Buzz
13%
Earning Acce
No
Dist 52w H.
26%Relative Strength
SPRY
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How SPRY compares to sector?
